Skip to content

Fennec Pharmaceuticals Inc.

FENC· NasdaqCore metricsCIK 1211583

Biological products, except diagnostic substances175 peers

Last sale
Nov 9, 2026 · +10.62%
Market cap
$381.38M
35.22M shares
Filings
855
$19.61M
Q3 2026−6.1% FY25 yoy
$4.64M
Q3 2026N/M FY25 yoy
$4.65M
Q3 2026N/M FY25 yoy
-$443.00K
Q3 2014derivedN/M FY13 yoy
$0.12
Q3 2026N/M FY25 yoy
$48.68M
Q3 2026+38.1% FY25 yoy
$381.38M
188.1×
5.7×
7.8×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$10.83+40.47%+$3.12past year
Nov 9, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$44.64MFY 2025
$47.54M0FY 2013FY 2018FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$44,642,000reported
FY 20242024-12-31$47,538,000reported
FY 20232023-12-31$21,252,000reported
FY 20222022-12-31$1,535,000reported
FY 20192020-12-31$200,000reported
FY 20182018-12-31$0reported
FY 20172017-12-31$0reported
FY 20162016-12-31$0reported
FY 20152015-12-31$0reported
FY 20142014-12-31$0reported
FY 20132013-12-31$0reported

Segments

Products
Revenue by Products, FY2019 to FY2025FY2019FY2020Eniluracil royalty · FY2020 · $170.00KFY2022PEDMARK · FY2022 · $1.54MFY2023PEDMARK · FY2023 · $21.25MFY2024PEDMARK · FY2024 · $29.58MFY2025PEDMARK · FY2025 · $44.64M
LineFY2025ShareChange
PEDMARK$44.64M100%+50.9%
Eniluracil royalty———
Total$44.64M

From the 10-K filed Mar 27, 2026FENC

Biological products, except diagnostic substances

Fennec Pharmaceuticals Inc. is the 44th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Fennec Pharmaceuticals Inc. · CIK 1211583 · Engraved from SEC EDGAR